• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2015 年美国甲状腺协会指南与甲状腺叶切除术后促甲状腺激素抑制治疗

2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.

机构信息

Department of Otolaryngology - Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, USA.

School of Medicine, University of Virginia, Charlottesville, Virginia, USA.

出版信息

Head Neck. 2021 Feb;43(2):639-644. doi: 10.1002/hed.26524. Epub 2020 Oct 30.

DOI:10.1002/hed.26524
PMID:33124116
Abstract

BACKGROUND

2015 American Thyroid Association (ATA) guidelines recommended more conservative treatment in low-risk well-differentiated thyroid cancer (WDTC), stating that lobectomy alone may be sufficient. The guidelines further recommend mild thyroid-stimulating hormone (TSH) level suppression (0.5-2 mU/L) for this population. Our goal is to evaluate the natural history of patients undergoing lobectomy to determine the percentage that would require postoperative levothyroxine supplementation under these guidelines.

METHODS

Retrospective chart review of 168 patients that underwent lobectomy between 2010 and 2019 was performed. Preoperative and postoperative TSH values and the rate of patients prescribed levothyroxine were analyzed.

RESULTS

Thirty-five percent of patients were prescribed levothyroxine postoperatively. At 6 weeks postoperatively, 66% had TSH value of >2; this increased to 76% by 6 to 12 months.

CONCLUSION

To adhere to ATA guidelines for WDTC managed with lobectomy alone, the majority of patients (76%) would require postoperative levothyroxine supplementation. Low preoperative TSH was found to be the most significant predictor for postoperative TSH < 2.

摘要

背景

2015 年美国甲状腺协会(ATA)指南建议对低危分化型甲状腺癌(WDTC)采用更保守的治疗方法,指出单纯腺叶切除术可能就足够了。该指南还建议对这部分人群进行轻度甲状腺刺激素(TSH)水平抑制(0.5-2mU/L)。我们的目标是评估行腺叶切除术患者的自然病程,以确定在这些指南下有多少患者需要术后补充左甲状腺素。

方法

对 2010 年至 2019 年间行腺叶切除术的 168 例患者进行回顾性图表审查。分析了术前和术后 TSH 值以及开处左甲状腺素的患者比例。

结果

术后 35%的患者需要服用左甲状腺素。术后 6 周时,66%的患者 TSH 值>2;6-12 个月时,这一比例增至 76%。

结论

为了遵守 ATA 关于单纯行腺叶切除术治疗 WDTC 的指南,大多数患者(76%)需要术后补充左甲状腺素。研究发现,术前 TSH 水平较低是术后 TSH<2 的最显著预测因素。

相似文献

1
2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.2015 年美国甲状腺协会指南与甲状腺叶切除术后促甲状腺激素抑制治疗
Head Neck. 2021 Feb;43(2):639-644. doi: 10.1002/hed.26524. Epub 2020 Oct 30.
2
Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.分化型甲状腺癌行甲状腺叶切除术后甲状腺激素替代治疗的频率。
Endocr Pract. 2021 Jul;27(7):691-697. doi: 10.1016/j.eprac.2021.01.004. Epub 2021 Jan 15.
3
Prediction of thyroid hormone supplementation after thyroid lobectomy.甲状腺叶切除术后甲状腺激素补充的预测。
J Surg Res. 2015 Jan;193(1):273-8. doi: 10.1016/j.jss.2014.07.003. Epub 2014 Jul 5.
4
Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.甲状腺刺激激素抑制与甲状腺叶切除术后甲状腺乳头状癌复发。
Endocrine. 2022 Feb;75(2):487-494. doi: 10.1007/s12020-021-02911-x. Epub 2021 Oct 23.
5
Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.甲状腺叶切除术后低危乳头状甲状腺癌患者是否可避免补充甲状腺激素?一项双中心观察性研究。
Clin Endocrinol (Oxf). 2022 Mar;96(3):413-418. doi: 10.1111/cen.14580. Epub 2021 Aug 16.
6
Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?肺叶切除术治疗分化型甲状腺癌:患者能否避免术后补充甲状腺激素并遵循美国甲状腺协会指南?
Surgery. 2018 Jan;163(1):75-80. doi: 10.1016/j.surg.2017.04.039. Epub 2017 Nov 7.
7
Postoperative thyroid hormone supplementation rates following thyroid lobectomy.甲状腺叶切除术后甲状腺激素补充率。
Am J Surg. 2020 Nov;220(5):1169-1173. doi: 10.1016/j.amjsurg.2020.06.052. Epub 2020 Jul 1.
8
Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.甲状腺叶切除术后停用左甲状腺素治疗甲状腺乳头状癌的成功率与良性肿瘤相当,与促甲状腺激素抑制的持续时间无关。
Anticancer Res. 2021 Nov;41(11):5713-5721. doi: 10.21873/anticanres.15387.
9
Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up.甲状腺癌术后行甲状腺激素补充治疗:5 年随访。
Front Endocrinol (Lausanne). 2020 Jul 31;11:520. doi: 10.3389/fendo.2020.00520. eCollection 2020.
10
Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.影响甲状腺乳头状癌术后患者促甲状腺激素抑制疗效的因素:一项回顾性队列研究
BMC Surg. 2024 May 3;24(1):133. doi: 10.1186/s12893-024-02426-y.

引用本文的文献

1
Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions.分化型甲状腺癌中促甲状腺激素抑制的个体化:证据、争议及未来方向
Endocrine. 2025 Apr 9. doi: 10.1007/s12020-025-04223-w.
2
Predicting central lymph node metastasis in papillary thyroid carcinoma combined with Hashimoto's thyroiditis: a preoperative study.预测合并桥本甲状腺炎的乳头状甲状腺癌中央淋巴结转移:一项术前研究
BMC Cancer. 2025 Mar 10;25(1):425. doi: 10.1186/s12885-025-13805-w.
3
Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
影响甲状腺乳头状癌术后患者促甲状腺激素抑制疗效的因素:一项回顾性队列研究
BMC Surg. 2024 May 3;24(1):133. doi: 10.1186/s12893-024-02426-y.
4
Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer.促甲状腺激素在甲状腺癌患者临床疗效中的价值及安全性分析
World J Clin Cases. 2023 Feb 16;11(5):1058-1067. doi: 10.12998/wjcc.v11.i5.1058.